EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Biomarkers of Aggressive Prostate Cancer at Diagnosis

Brock E Boehm, Monica E York iD, Gyorgy Petrovics, Indu Kohaar, Gregory T Chesnut

International Journal of Molecular Sciences · 22.01.2023 · 24 (3) · 2185

DOI: 10.3390/ijms24032185 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.01.2023. Verfasst von Brock E Boehm und 4 weiteren Autor:innen. Beteiligte Einrichtung: Urology Service, Walter Reed National Military Medical Center, Bethesda, MD 20814, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 84-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI Early Detection Research Network (EDRN).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the United States, prostate cancer (CaP) remains the second leading cause of cancer deaths in men. CaP is predominantly indolent at diagnosis, with a small fraction (25–30%) representing an aggressive subtype (Gleason score 7–10) that is prone to metastatic progression. This fact, coupled with the criticism surrounding the role of prostate specific antigen in prostate cancer screening, demonstrates the current need for a biomarker(s) that can identify clinically significant CaP and avoid unnecessary biopsy procedures and psychological implications of being diagnosed with low-risk prostate cancer. Although several diagnostic biomarkers are available to clinicians, very few comparative trials have been performed to assess the clinical effectiveness of these biomarkers. It is of note, however, that a majority of these clinical trials have been over-represented by men of Caucasian origin, despite the fact that African American men have a 1.7 times higher incidence and 2.1 times higher rate of mortality from prostate cancer. Biomarkers for CaP diagnosis based on the tissue of origin include urine-based gene expression assays (PCA3, Select MDx, ExoDx Prostate IntelliScore, Mi-Prostate Score, PCA3-PCGEM1 gene panel), blood-based protein biomarkers (4K, PHI), and tissue-based DNA biomarker (Confirm MDx). Another potential direction that has emerged to aid in the CaP diagnosis include multi-parametric magnetic resonance imaging (mpMRI) and bi-parametric magnetic resonance imaging (bpMRI), which in conjunction with clinically validated biomarkers may provide a better approach to predict clinically significant CaP at diagnosis. In this review, we discuss some of the adjunctive biomarker tests along with newer imaging modalities that are currently available to help clinicians decide which patients are at risk of having high-grade CaP on prostate biopsy with the emphasis on clinical utility of the tests across African American (AA) and Caucasian (CA) men.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsMaleHumansUnited StatesProstateProstate-Specific AntigenEarly Detection of CancerBiopsyBiomarkers, Tumor

Stichwörter der Autor:innen

biomarkersdiagnosisprostate cancerrace

Substanzen

Prostate-Specific AntigenBiomarkers, Tumor

Autor:innen und Institutionen

  • Urology Service, Walter Reed National Military Medical Center, Bethesda, MD 20814, USA.
  • School of Medicine, Uniformed Services University of Health Science, Bethesda, MD 20814, USA.
  • Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, MD 20814, USA.
  • Henry Jackson Foundation for the Advancement of Military Medicine (HJF), Bethesda, MD 20817, USA.

ORCID-Profile: Monica E York

Förderung

  • NCI Early Detection Research Network (EDRN)

Zitieren

APA

Boehm, B. E., York, M. E., Petrovics, G., Kohaar, I., & Chesnut, G. T. (2023). Biomarkers of Aggressive Prostate Cancer at Diagnosis. International Journal of Molecular Sciences, 24(3), 2185. https://doi.org/10.3390/ijms24032185

Vancouver

Boehm BE, York ME, Petrovics G, Kohaar I, Chesnut GT. Biomarkers of Aggressive Prostate Cancer at Diagnosis. International Journal of Molecular Sciences. 2023;24(3):2185. doi:10.3390/ijms24032185

BibTeX
@article{Boehm2023,
  author = {Boehm, Brock E and York, Monica E and Petrovics, Gyorgy and Kohaar, Indu and Chesnut, Gregory T},
  title = {Biomarkers of Aggressive Prostate Cancer at Diagnosis},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {3},
  pages = {2185},
  doi = {10.3390/ijms24032185}
}
Kostenlos starten →